Reducing Treatment Burden in AMD

Rajendra S. Apte

doi:10.1016/j.cell.2020.02.028

Reducing Treatment Burden in AMD

Rajendra S. Apte

Research output: Contribution to journal › Comment/debate

12 Scopus citations

Abstract

VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity, favored brolucizumab. To view this Bench to Bedisde, open or download the PDF.

Original language	English
Pages (from-to)	1033
Number of pages	1
Journal	Cell
Volume	180
Issue number	6
DOIs	https://doi.org/10.1016/j.cell.2020.02.028
State	Published - Mar 19 2020

Access to Document

10.1016/j.cell.2020.02.028

Cite this

@article{3c27496e866e412a9c949c6af8e21740,

title = "Reducing Treatment Burden in AMD",

abstract = "VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity, favored brolucizumab. To view this Bench to Bedisde, open or download the PDF.",

author = "Apte, {Rajendra S.}",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = mar,

day = "19",

doi = "10.1016/j.cell.2020.02.028",

language = "English",

volume = "180",

pages = "1033",

journal = "Cell",

issn = "0092-8674",

number = "6",

}

TY - JOUR

T1 - Reducing Treatment Burden in AMD

AU - Apte, Rajendra S.

PY - 2020/3/19

Y1 - 2020/3/19

N2 - VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity, favored brolucizumab. To view this Bench to Bedisde, open or download the PDF.

AB - VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity, favored brolucizumab. To view this Bench to Bedisde, open or download the PDF.

UR - http://www.scopus.com/inward/record.url?scp=85081669038&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2020.02.028

DO - 10.1016/j.cell.2020.02.028

M3 - Comment/debate

C2 - 32200797

AN - SCOPUS:85081669038

SN - 0092-8674

VL - 180

SP - 1033

JO - Cell

JF - Cell

IS - 6

ER -

Reducing Treatment Burden in AMD

Abstract

Access to Document

Other files and links

Fingerprint

Cite this